LOS ALTOS, Calif., Oct. 17, 2016 /PRNewswire/ -- Globavir Biosciences, Inc., a biotechnology company that develops therapeutics for infectious diseases and oncology, and diagnostics for infectious diseases, announced a partnership with Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostics products. Under the terms of the agreement, Bio-Rad will license Globavir’s PanGlob dengue detection technology for use in an assay that includes dengue virus detection. Financial terms of the agreement were not disclosed.
The PanGlob assay, originally developed by Stanford University researchers, includes improved diagnostic sensitivity, efficacy across all four dengue serotypes, and enhanced specificity for dengue over related viruses. This advanced technology reduces the risk of incorrect results.
“Infectious disease outbreaks are a threat to human health with the potential of quickly reaching an epidemic level,” said Globavir CEO Dr. Shalabh Gupta. “Correct diagnosis of these types of diseases is the crucial first step toward effective patient care and surveillance. Globavir is excited to lend our dengue technology toward the creation of this important assay.”
“Bio-Rad is pleased to partner with Globavir for a dengue assay that provides improved sensitivity and specificity in detecting this virus,” said Bio-Rad President Clinical Diagnostics Group John Hertia.
About Dengue
Dengue is a mosquito-borne viral infection that causes flu-like illness that can develop into a potentially lethal complication called severe dengue. According to the World Health Organization, the global incidence of dengue has grown dramatically in recent decades, with about half of the world’s population now at risk. Driven by increased travel of asymptomatic patients and the global spread of the disease-carrying mosquito, a recent estimate reports that dengue infection affects approximately 390 million patients worldwide, with nearly 100 million of these cases manifesting with consequences ranging from the painful and debilitating dengue fever to severe dengue. Dengue is endemic in more than 100 countries in the WHO regions of Africa, the Americas, the Eastern Mediterranean, South-East Asia and the Western Pacific. Although there is no specific treatment for dengue or severe dengue, early detection and access to proper medical care lowers fatality rates below one percent.
About Globavir
Globavir Biosciences is a biotechnology company developing life-saving technologies for treatment of oncology and infectious diseases. Globavir is developing powerful combination drug therapies and diagnostic tests for the treatment of dengue fever. Globavir, based in Los Altos, California, USA, has rights to develop and commercialize a dengue diagnostic test platform developed at Stanford University. Globavir’s diagnostic kits have received CE-mark approval and are currently being marketed globally. The company has the leading molecular diagnostic test to detect dengue infection as well as a platform for other virus detection tests. Additionally, Globavir has multiple oncology drugs in development.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 8,000 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com
Logo - http://photos.prnewswire.com/prnh/20140818/137091
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/globavir-announces-licensing-agreement-with-bio-rad-for-globavirs-dengue-detection-technology-300345449.html
SOURCE Globavir Biosciences, Inc.
